Liminal Biosciences Inc

+0.01 (+0.25%)
Officer Changes, Earnings Announcements

Liminal BioSciences Reports Third Quarter Financial Results

Published: 11/12/2020 22:11 GMT
Liminal BioSciences Inc. (LMNL) - Liminal Biosciences Reports Third Quarter Financial Results.
Liminal Biosciences - Kenneth Galbraith Tendered Resignation As CEO and As Member of Board for Personal Reasons, Effective Nov.
Liminal Biosciences - Bruce Pritchard & Patrick Sartore Have Agreed to Act in Capacity of CEO & President, Respectively.
Liminal Biosciences Inc - Galbraith Will Be Involved in Transition of CEO Duties to Mr. Pritchard.
Liminal Biosciences Inc - Net Loss From Continuing Operations Was $23.3 Million for Q3 of 2020 Compared to $29.6 Million.
Revenue is expected to be $0.46 Million
Adjusted EPS is expected to be -$0.47

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.